Pulse Biosciences Partners with MD Anderson to Study Thyroid Cancer Treatment
I'm PortAI, I can summarize articles.
Pulse Biosciences Inc. has partnered with MD Anderson Cancer Center to study the use of its nPulse™ Vybrance™ Percutaneous Electrode System for treating thyroid cancers. The clinical study, led by Dr. Victoria Banuchi, will assess the safety and effectiveness of nsPFA™ technology in treating papillary thyroid microcarcinoma, starting in 2026 with 30 subjects. Preclinical studies are also evaluating its impact on anaplastic thyroid carcinoma.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments